天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ABT-263

ABT-263 Struktur
923564-51-6
CAS-Nr.
923564-51-6
Englisch Name:
ABT-263
Synonyma:
Navitoclax;Navitoclax (ABT-263);ABT 263;CS-1871;CS-1967;Navitoclax-D8;ABT263;ABT-263;Navitoclax, >=98%;ABT 263 USP/EP/BP;ABT-263,Navitoclax
CBNumber:
CB21872884
Summenformel:
C47H55ClF3N5O6S3
Molgewicht:
974.61
MOL-Datei:
923564-51-6.mol

ABT-263 Eigenschaften

Schmelzpunkt:
114-116°C
Dichte
1.41±0.1 g/cm3(Predicted)
storage temp. 
-20°C Freezer, Under Inert Atmosphere
L?slichkeit
Soluble in DMSO (up to 25 mg/ml).
Aggregatzustand
solid
pka
4.60±0.10(Predicted)
Farbe
White
Stabilit?t:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
InChIKey
JLYAXFNOILIKPP-KXQOOQHDSA-N
SMILES
C(NS(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN2CCOCC2)C(S(C(F)(F)F)(=O)=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CC(C)(C)CCC=3C3=CC=C(Cl)C=C3)CC2)C=C1
CAS Datenbank
923564-51-6

Sicherheit

HS Code  29339900

ABT-263 Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften

Pale Yellow Solid

Verwenden

A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate.

Mechanism of action

ABT‐263 exerts its senolytic activity in senescent tumor cells by inhibiting BCL‐XL's interaction with BAX. ABT‐263 is a BH3 mimetic that inhibits anti‐apoptotic BCL‐2 family proteins by impeding their ability to bind pro‐apoptotic proteins, such as BAK and BAX. BCL‐2 and BCL‐XL are the primary targets of ABT‐263 in cancer cells. 

Pharmakokinetik

The pharmacokinetic profile of ABT-263 is characterized by low plasma clearance values and low volumes of distribution in mice, rats, dogs, and monkeys, with plasma elimination half-lives after i.v. Dose of 4.6 to 8.4 hours. Bioavailability after oral gavage was ~20% in all four species. Due to its low aqueous solubility, ABT-263 displays a prolonged dissolution rate-limited oral absorption. P.o. administration in lipid-based formulations, in which the compound is significantly more soluble, yields enhanced absorption with bioavailability near 50% and an oral elimination half-life of 8.9 hours in dogs[5].

ABT-263 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ABT-263 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 239)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32957 60
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29791 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21634 55
Hangzhou FandaChem Co.,Ltd.
+8615858145714
FandaChem@Gmail.com China 9087 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29880 58
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
sales@tianpharm.com CHINA 304 58
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 965 58
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830
figo.gao@foxmail.com China 8497 58
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22963 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58

923564-51-6()Verwandte Suche:


  • 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
  • ABT 263
  • BenzaMide, 4-(4-((2-(4-chlorophenyl)-5,5-diMe
  • Benzamide, 4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylthio)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-
  • ABT-263,Navitoclax
  • (S)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
  • 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide ABT-26
  • ABT 263 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
  • Navitoclax, >=98%
  • (S)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperaz
  • (R)-4-(4-((2-(4-Chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morph
  • ABT263;ABT-263
  • 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
  • CS-1871
  • CS-1967
  • (R)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(4-(4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide
  • NAVITOCLAX;ABT 263;ABT263
  • (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
  • ABT 263, 98%, potent inhibitor of Bcl-xL,Bcl-2 and Bcl-w
  • (R)-4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[3-morpholino-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide
  • ABT 263 USP/EP/BP
  • Navitoclax-D8
  • Navitoclax
  • Navitoclax (ABT-263)
  • ABT-263(Navitoclax)/ABT263
  • (R)-4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
  • 923564-51-6
  • 23564-51-6
  • C47H55ClF3N5O6S3
  • Inhibitor
  • Apis
  • Chiral Reagents
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Copyright 2019 ? ChemicalBook. All rights reserved